NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

PharmaCyte Biotech Inc (OTCQB: PMCBD)

PMCBD Technical Analysis
As on 8th Oct 2021 PMCBD STOCK Price closed @ 3.19 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.31 & Strong Buy for SHORT-TERM with Stoploss of 0.01 we also expect STOCK to react on Following IMPORTANT LEVELS.


Open 3.05 Change Price %
High 3.20 1 Day 0.19 6.33
Low 3.00 1 Week 0.17 5.63
Close 3.19 1 Month -0.15 -4.49
Volume 758217 1 Year 3.18 31800.00
52 Week High 16.90 | 52 Week Low 0.00
OTCQB USA Most Active Stocks
BMIX 0.01 %
MOBQ 0.18 %
FNMA 0.45 %
ALPP 3.56 0.00%
ALPP 3.56 0.00%
SHMP 0.06 %
NWBO 0.73 %
VPLM 0.08 %
NLST 3.72 %
SRNA 2.78 14.88%
OTCQB USA Top Gainers Stocks
EWLUD 0.45 275.00%
HCAND 0.02 100.00%
PMMCF 0.34 55.56%
PMMCF 0.34 55.56%
TUMIF 0.09 50.00%
EXDI 0.82 38.98%
NVMDF 0.27 35.00%
NVMDF 0.27 35.00%
GYRRF 0.24 33.33%
QTRRF 0.10 25.00%
OTCQB USA Top Losers Stocks
ETST 0.03 -25.00%
ETST 0.03 -25.00%
FDMSF 0.03 -25.00%
EMPR 19.46 -20.73%
EMPR 19.46 -20.73%
IFNY 0.04 -20.00%
UBMRD 0.56 -15.15%
HARY 0.06 -14.29%
HARY 0.06 -14.29%
NPDCF 0.06 -14.29%
Daily Charts
Intraday Charts
Whats New @
Free Analysis
PMCBD Important Levels Intraday
PMCBD Forecast September 2023
4th UP Forecast3.21
3rd UP Forecast3.2
2nd UP Forecast3.2
1st UP Forecast3.2
1st DOWN Forecast3.18
2nd DOWN Forecast3.18
3rd DOWN Forecast3.18
4th DOWN Forecast3.17
PMCBD Weekly Forecast
4th UP Forecast3.19
3rd UP Forecast3.19
2nd UP Forecast3.19
1st UP Forecast3.19
1st DOWN Forecast3.19
2nd DOWN Forecast3.19
3rd DOWN Forecast3.19
4th DOWN Forecast3.19
PMCBD Forecast2023
4th UP Forecast35.76
3rd UP Forecast25.31
2nd UP Forecast18.86
1st UP Forecast12.4
1st DOWN Forecast-6.02
2nd DOWN Forecast-12.48
3rd DOWN Forecast-18.93
4th DOWN Forecast-29.38
PMCBD Other Details
Segment EQ
Market Capital 14317920.00
Sector Healthcare
Industry Biotechnology
Offical website >
PMCBD Address
PMCBD Latest News
Your Comments and Response on PharmaCyte Biotech Inc
PMCBD Business Profile
PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California. Address: 23046 Avenida de la Carlota, Laguna Hills, CA, United States, 92653
2005-2023 All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service